Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia

Kiran Naqvi, Elias Jabbour, Jeffrey Skinner, Musa Yilmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip Thompson, Yesid Alvarado, Nitin Jain, Koichi Takahashi, Jan Burger, Zeev Estrov, Gautam Borthakur, Naveen Pemmaraju, Shilpa Paul, Jorge Cortes, Hagop M. Kantarjian

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Fingerprint Dive into the research topics of 'Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences